Skip to content

Bristol-Myers Squibb

US · BMY #158 by market cap Listed 1970
58.80 +0.46 +0.79%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Distributing
  • The number of reporting institutions decreased by 8 in the most recent period (2026/Q4).
  • Total institutional ownership fell 0.1 percentage points.

Ownership vs. money flow

Diverging

Institutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
83.65% -0.12pp
Institutions
3,023 -8
As of
2026/Q4 vs. prior period

Holder types

Mutual Fund69.33%
Public Company3.61%
Hedge Fund2.86%
Government Pension Fund2.63%
Private Company2.16%
Sovereign Wealth Fund1.89%
Insurance Company0.33%
Family Office/Trust0.30%
VC/PE Fund0.17%
Corporate Pension Plan0.16%
Other16.73%

Top holders as of 2026-09-30

BlackRock 8.50% · 173.66M sh
Vanguard Capital Management, LLC 7.10% · 145.22M sh
State Street Global Advisors 5.06% · 103.34M sh
Charles Schwab Investment Management 3.54% · 72.46M sh
Geode Capital Management, LLC 2.48% · 50.64M sh
Other 72.86%
J.P. Morgan Asset Management, Inc. 2.40% · 49.06M sh
Vanguard Portfolio Management, LLC 2.30% · 47.06M sh
Norges Bank Investment Management 1.80% · 36.87M sh
UBS Asset Management 1.59% · 32.45M sh
T. Rowe Price Group, Inc. 1.35% · 27.55M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 33 buys · 17 sells

NameRoleStake
Sandra Leung Former Executive Vice President 0.02%
David Elkins Chief Financial Officer 0.01%
Christopher Boerner Chairperson & CEO 0.01%
Theodore Samuels Lead Independent Director 0.00%
Greg Meyers Executive VP and Chief Digital & Technology Officer 0.00%
Adam Lenkowsky Executive VP & Chief Commercialization Officer 0.00%
Samit Hirawat Former Executive VP, Chief Medical Officer & Head of Development 0.00%
Karin Shanahan Executive VP, Chief Supply Chain & Operations Officer 0.00%
Julia Haller Independent Director 0.00%
Robert Plenge Executive VP & Chief Research Officer 0.00%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-11-04 Julia Haller Independent Director Open Market Disposition -3,800 $63.31
2026-11-02 Adam Lenkowsky Executive VP & Chief Commercialization Officer Derivative Exercise and Sale -3,848 $61.71
2026-11-02 Adam Lenkowsky Executive VP & Chief Commercialization Officer Derivative Exercise and Retained +3,674 --
2026-10-31 Christopher Boerner Chairperson & CEO Sale to Issuer -1,724 $62.48
2026-10-31 Christopher Boerner Chairperson & CEO Other Acquisition +406 --
2026-10-31 Christopher Boerner Chairperson & CEO Derivative Exercise and Retained +2,964 --
2026-10-31 Greg Meyers Executive VP and Chief Digital & Technology Officer Derivative Exercise and Sale -2,665 $62.48
2026-10-31 Greg Meyers Executive VP and Chief Digital & Technology Officer Derivative Exercise and Retained +3,616 --
2026-10-31 Karin Shanahan Executive VP, Chief Supply Chain & Operations Officer Derivative Exercise and Sale -3,213 $62.48
2026-10-31 Karin Shanahan Executive VP, Chief Supply Chain & Operations Officer Derivative Exercise and Retained +3,068 --
2026-10-01 Cari Gallman Executive VP, General Counsel & Chief Policy Officer Derivative Exercise and Sale -2,332 $61.15
2026-10-01 Cari Gallman Executive VP, General Counsel & Chief Policy Officer Derivative Exercise and Retained +2,227 --
2026-09-29 Derica Rice Independent Director Other Derivative Acquisition +620 --
2026-09-29 Phyllis Yale Independent Director Other Derivative Acquisition +560 --
2026-09-29 Peter Arduini Independent Director Other Derivative Acquisition +560 --
2026-09-29 Theodore Samuels Lead Independent Director Other Derivative Acquisition +821 --
2026-09-29 Michael McMullen Independent director Other Derivative Acquisition +560 --
2026-09-08 Cristian Massacesi Executive VP, Chief Medical Officer & Head of Development Open Market Disposition -6,249 $64.57
2026-08-31 Wendy Bartie Executive VP & Chief Corporate Affairs Officer Derivative Exercise and Sale -633 $66.92
2026-08-31 Wendy Bartie Executive VP & Chief Corporate Affairs Officer Derivative Exercise and Retained +603 $66.92

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.

Bristol-Myers Squibb discussion 0 comments

Add a comment